J&J targets 2024 for Ottava FDA filing
The company expects to file a submission for an investigational device exemption in the second half of 2024 that will allow it to begin clinical trials for the robotic surgery system.
Uncategorized
Zimmer Biomet’s Ivan Tornos sets priorities for first year as CEO
Tornos, who took the helm in August, said the company will grow through internal innovation and M&A.
Zimmer Biomet’s Ivan Tornos sets priorities for first year as CEO Read More »
Biden administration proposes capping broker payment in MA, following pressure
The CMS proposed a rule on Monday to stop brokers from steering beneficiaries to plans based on excessive compensation. It’s regulators’ latest move to curb Medicare Advantage marketing misconduct following a push from lawmakers.
Biden administration proposes capping broker payment in MA, following pressure Read More »
BioSpace Announces 2024 Best Places to Work in Biopharma
BioSpace has published its annual 2024 Best Places to Work list.
BioSpace Announces 2024 Best Places to Work in Biopharma Read More »
Preparing for the future: Hospital climate resilience plans challenged by cost, uncertainty
As extreme weather events caused by climate change ramp up in frequency, hospitals are struggling with financial and data challenges in disaster planning.
Autobahn Therapeutics Announces Positive Topline Results from Phase 1 Study of ABX-002, its Lead Oral Treatment for Major Depressive Disorder
Autobahn Therapeutics today announced positive topline results from a first-in-human Phase 1 clinical study assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of escalating doses of ABX-002 in healthy volunteers.
Grace Science Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Phase 1/2/3 Trial for the Treatment of NGLY1 Deficiency with GS-100, an AAV9 NGLY1 Gene Therapy
Grace Science, LLC announced today that it has received FDA clearance of its Investigational New Drug (IND) application for GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 Deficiency.
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial
BostonGene and LegoChem Biosciences, Inc. announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers.
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
MAIA Biotechnology, Inc. today reported financial results for the third quarter ended September 30, 2023 and key operational updates.
Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today
BioArctic AB’s partner Eisai held a presentation on the second quarter of Eisai’s fiscal year, ending March 2024.